Decreases the liver's production of glucose
Case identification was performed through drug name queries in the DRUG table, with subsequent filtering restricted to Primary Suspect (PS) cases
2A), and at 2 min ( p = 0.042), 3 min ( p = 0.039), 4 min ( p = 0.048), 5 min ( p = 0.017), 7 min ( p = 0.027), 8 min ( p = 0.017), 9 min ( p = 0.039), 10 min ( p = 0.039), and 11 min ( p = 0.017) during the experimental protocol (Fig
Food and Drug Administration Interim 503A Bulks List Category 2 / PCAC review notices for CJC-1295 (free base, acetate, DAC variants), ipamorelin, AOD-9604, and thymosin alpha-1
5 Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea